Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You seek long term if Sycamore buys?...LOL !!
Penny Stocks are your "Long Term " idea of investing?...Wait wait , don't tell me..You think JCP is a Gem no matter who buys it ?...LOL !!
...and You Think you'll see an Equal Bounce ?
...Amazon Brings ALL Prime Members....A Saudi Prince brings GRANDMA
Without Amazon JCP is Just a Struggling Department store.
it matters that an Amazon buyout would peak more interest from ALL walks of life....Especially Prime Members.
Amazon has The World of Inventory.
..Dead Cat bounces would likely go higher and last longer.
..JCPenney just surviving by Sycamore won't attract as much money...it's only a struggling department store without Amazon who bring value with it's Amazon Prime members. ( shoppers )
Positive or Negative views on a message board won't change the PPS...LOL !!
One can only wish their voice was that powerful.
....But Good Luck with That !!....LOL !!
Prime Members would skyrocket it..Otherwise it's just JCPenney
Sycamore not Amazon ?...BIG Difference, Much Weaker Bounce.
Be Careful with this Bounce People, A " possible " Sycamore deal won't carry as far.
I appreciate your input...I really do...It's good to hear both sides as I try not to wear " rose colored glasses " with any stock .
.... I don't think exchanging views on a Large Cap message board ( positive or negative ) affects the PPS .....maybe on the OTC but not here....but good luck to those that think it does.
My portfolio is diverse enough for me not to lose sleep over GILD , but I do monitor my investments daily and in 20 years I've never married any stock
...I'm currently good with GILD.... Do I wish it were better ?...sure but no stock is perfect .
You Said:
Slack (WORK) - reported revenue of $201.7 million, up 50% year over year, and a non-GAAP loss per share of 2 cents. Analysts polled by FactSet were expecting sales of $188.5 million and a non-GAAP loss of 6 cents per share.
However, the company withdrew its full-year guidance for calculated billings -- a metric often viewed as a bellwether for future revenue -- citing "ongoing uncertainties surrounding the COVID-19 pandemic," according to a press release.
The 5 day treatment is their goal now...I'm back in on an upgrade from 15 minutes ago.... ( 5 day treatment instead of the 10 day )
This quote is from 2 days ago
I'm playing it slow myself now ..... keywords " moderate effect " and "mixed results" have shown up in MULTIPLE press releases since yesterday.
As much as like GILD that tends to put me on the defensive.
Why do you say that?...saying that without giving a reason doesn't hold water.
Thanks very much...It's good to see CEO Daniel O’Day collaborating with former employer Roche Holding AG on giving Covid-19 a " Double Tap "... aka " A One-Two Punch "
....(imo) It's a positive step towards full FDA approval as Roche Holding AG likely feels confident with Remdesivir's Phase 3 trials as a 2nd wave hits South Korea and Brazil reaches grim milestones daily.
Roche's Actemra is used to treat inflammatory diseases and to control the cytokine storms associated with certain immuno-oncology treatments.
Gilead’s remdesivir is an antiviral drug. COVID-19 is marked by several unusual symptoms, including blood clotting, cytokine storms and severe pneumonia.
Gilead Gets an Upgrade With Street Mulling Remdesivir Profit
May 26, 2020, Bloomberg
Tik-Tok Tik-Tok Estimated Study Completion Date: May 2020
Merck is relatively cheap with a p/e multiple of under 14 and a dividend yield of 3.19%, according to Macrotrends.
Merck also has an excellent track record when it comes to earnings. It has beaten earnings-per-share estimates in 25 consecutive quarters
https://www.macrotrends.net/stocks/charts/mrk/merck/pe-ratio
It's (honestly) good to hear you say that, and I agree that MRNA is a good play.......no stock is perfect.
Earnings were volatile BUT MRNA earnings expectations are higher for the coming year (-$1.45 versus -$1.54).
It's overbought but once it settles ...WOW Cha-Ching !!
I'll Play the Dead Cats ( up on no news )
Revenue fell faster than the subsector average of 8.9%.
Since the same quarter one year ago, revenues fell by 47.6%
From The Street Quant Ratings : RECOMMENDATION We rate ASTRAZENECA PLC (AZN) a BUY.
This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. Among the primary strengths of the company is its solid stock price performance.
We feel its strengths outweigh the fact that the company has had sub par growth in net income. HIGHLIGHTS Compared to its closing price of one year ago, AZN's share price has jumped by 45.93%, exceeding the performance of the broader market during that same time frame.
We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its subsector. The other strengths this company shows, however, justify the higher price levels.
ASTRAZENECA PLC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past two years. However, we anticipate this trend to reverse over the coming year.
During the past fiscal year, ASTRAZENECA PLC reported lower earnings of $0.53 versus $0.86 in the prior year. This year, the market expects an improvement in earnings ($1.97 versus $0.53). AZN, with its decline in revenue, slightly underperformed the subsector average of 3.3%. Since the same quarter one year prior, revenues slightly dropped by 3.1%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
The debt-to-equity ratio of 1.39 is relatively high when compared with the subsector average, suggesting a need for better debt level management.
To add to this, AZN has a quick ratio of 0.62, this demonstrates the lack of ability of the company to cover short-term liquidity needs.
Current return on equity is lower than its ROE from the same quarter one year prior. This is a clear sign of weakness within the company. In comparison to the other companies in the Chemical Manufacturing subsector and the overall market, ASTRAZENECA PLC's return on equity is significantly below that of the subsector average and is below that of the S&P 500.
It's from Cramers site...The " paid subscription " section....so no link. ( sorry )
...Abbott Laboratories is in their portfolio.
RISKS: Emerging market exposure, Product disruptions, strong dollar, timing of FDA approvals.
INVESTMENT THESIS: Strong underlying performance evidenced by sustained strength in organic sales growth.
The company boasts high-performing franchises in Medical Devices (with strong growth in Diabetes Care) and Diagnostics (with strong gains in Core Laboratory), while Nutrition and Established Pharmaceutical remain strategic parts of its total portfolio.
We believe the company's opportunities for upside rest with additional Libre uptake, the Alinity U.S. launch, and an expanded indication of the MitraClip.
We believe in incoming CEO Robert Ford and the rest of the Abbott management team, which has a strong track record of integrating acquisitions and delivering double-digit earnings per share growth. Lastly, Abbott has plenty of financial flexibility to pursue mergers/acquisitions and other strategic actions.
I appreciate your info....MRNA wants us to buy but being new to this ticker I'm having concerns about Phase 3 Transparency...any posts are appreciated.
..Please note, I'm neutral and just getting back to IHUB but have been on IHUB years ago....I respect all sides....Thanks .
You know who wouldn't?...Exec's that have confidence in the company
Yes, of course all exec's do it in these situations...It Helps the PPS go UP,,,Not Down...Right ??....$30 Million , No Big Deal..HAHAHAHAHA
...Maybe You Want Smoke Blown in Your Face but I Don't.
Oh so This looks good for MRNA ? LOL !!!
$30M No Big Deal ?? LOL !
....It Shows Lack of Confidence in the company moving forward.
Clearly you see this with rose-colored glasses.
...Good Luck to you sir.
Top execs dumped $30 million of MRNA stock https://www.cnn.com/2020/05/22/investing/moderna-coronavirus-vaccine-stock-sales/index.html
The Honk Kong uprising will hurt the PPS as Trade Wars tension escalates
Thanks for ALL your posts...5G and China Tensions: Where Does This Leave Qualcomm Shares?
Qualcomm (QCOM) - has had quite a run since its March 23, 2020 low and investors are right to look through what will be a less exciting 2020 than initially thought, according to one analyst.
Qualcomm is up 30% since that low, but still down for the year as earnings for 2020 have been revised lower on account of coronavirus. Semiconductor stocks have enjoyed a big run up and, like many stocks in the U.S. market, are now trading at elevated valuations on next 12 month’s earnings. Although part of the reason is lowered interest rates, investors are looking for a sharp recovery into the end of the year.
But Qualcomm now trades at 17 times 2020 earnings per share, using FactSet consensus estimates, compared to its recent average of roughly 16 times. The reason: 2021 is looking to be a strong year, especially as 5G handsets make their way through production and into the hands of users around the globe.
“Despite the near-term uncertain smartphone supply-and-demand environment, Qualcomm is well positioned to benefit from the long-term 5G investment cycle and anticipate recovering earnings in 2021 as 5G smartphones ramp, Apple reenters the model for QCT [a business segment] shipments, and global demand for smartphones improves,” wrote Canaccord Genuity analyst Michael Walkley in a note after hosting a meeting with management.
Economic activity is expected to recover in the second half of 2020, a trend currently looking much sharper in China than in the U.S. Excluding a second wave of virus outbreaks, this looks to be on track.
Walkley is looking for 5G handset volumes between 175 million and 225 million in calendar year 2020, not a far cry from previous 2020 estimates. Combined with other revenue segments, this would translate to about $20.25 billion in sales for Qualcomm.
But investors are more concerned with 2021 results and Walkley sees Qualcomm taking market share from other players in 5G chip sales in 2021, as the company is producing a powerful chip. Walkley is looking for revenue in 2021 to grow 29% to $26 billion, suggesting profit margins may expand too.
Walkley also points out that Huawei, which the White House is disallowing from buying U.S.-made chips, does not represent much revenue for Qualcomm. According to research from Alliance Bernstein analysts, Huawei only accounts for roughly 5% of global semiconductor purchases. And according to CFRA analysts, Huawei only comprises roughly 3% of Qualcomm’s revenue, allowing other revenue streams to outweigh Huawei’s impact.
Walkley has a $102 price target on Qualcomm shares, implying a 16.9 times multiple on his 2021 earnings forecast of $6.02 a share. Pre-virus, 5G-exposed chip makers were indeed trading at elevated multiples compared to their histories because the multi-year 5G ramp was expected to bring strong revenue and earnings growth. Walkley’s price target reflects 30% upside.
Risks to the thesis on Qualcomm: stronger 5G competition from other makers or another virus crisis, disabling suppliers from building and consumers from buying, although the latter argument is rebutted by the industry’s position that 5G devices would be highly beneficial during a pandemic period.
Ok so which one of you Warren Buffet wannabe
MFers bought 10,000,000 shares at the End Bell today ???
... Glad I didn't short this cause that is going to leave a mark tomorrow.
Westfield malls converting to curbside pickup , Therefore Amazon will need to buy JCP or risk missing out.
Thank's...I'm out for now...I bailed pre-market.....sorry about our squall yesterday.
..I usually find a middle ground with my opposition as I think it's important for boards to hear what's " Behind the curtain ".
It's been years for me but
I've played the bad guy myself, just ask the moderator here " Pistol Pete " , he might remember me from DECN 4 Years ago.
Anyway I'll keep an eye on NIO as Cramer only mentioned today on his site that earnings are next week....apparently they still like it,because it's still rated in their " Stocks I Would Buy Now " list.
They also like MOBL for the 2nd half of 2020...I'm the mod on that board but im out of that right now too haha.....OVV...APPS...NOK...DRRX..ERII...FTCH...ATRS...IWM...OESX...USAT....Just to name a few.
...ummmm Cramer is dumping ADT...Ok that's it for now cause I gotta go....again sorry about yesterday ...I'll be back after the dust settles.
...good luck to everyone as I just want to wait to hear about " Trade War news " before I get back in.
Seriously I'd do a ZOOM video show the Cars ....That would get my attention.
....Add a girls K-POP band to it and I'll throw my wallet with all my money at NIO
Earnings Video BEFORE next Thurs.is the way to go....Perhaps Monday?
US-China Commission Twitter page and U.S.-CHINA Economic and Security Review Commission homepage links:
US-China Commission Twitter:
https://twitter.com/USCC_GOV?ref_src=twsrc%5Etfw%7Ctwcamp%5Eembeddedtimeline%7Ctwterm%5Eprofile%3AUSCC_GOV&ref_url=https%3A%2F%2Fwww.uscc.gov%2F
U.S.-CHINA Economic and Security Review Commission homepage:
https://www.uscc.gov/
I'm starting to be on the fence about this.....Forced Audits aren't welcomed and The U.S. ( and I agree ) would love to get their hands on their financials, the Chinese are secretive and who knows what's hiding.
Yes, Tencent ( Ticker TCEHY ) has 12.6% beneficial ownership with aggregate voting power of 21.1% in NIO closed yesterday up 2.2% seemingly unphased but....
Meeting U.S. Regulatory actions might be more of a hurdle than just an audit.
....I wouldn't doubt some of the legit companies going private.
Concerning NASDAQ :
There are 156 Chinese companies listed on the NASDAQ with a total market capitalization of $1.2 trillion...... at least 11 Chinese state-owned companies listed on the three major U.S. exchanges.
Baidu is considering delisting as they (allegedly) feel undervalued on the U.S. NASDAQ market.....Will China Force the Hand of Others in Retaliation?
Privatizing:
....Some companies may just decide to go private....Will NIO ? Will Tencent ?
...again I don't think China doesn't take kindly to companies handing over documents. ( State-owned or not )
If the delistings happen investors will flock to sell their shares in a virtual race to the bottom.
Be Careful Today.
Hers the Link to the U.S.-CHINA ECONOMIC AND SECURITY REVIEW COMMISSION
https://www.uscc.gov/sites/default/files/Chinese%20Companies%20on%20U.S.%20Stock%20Exchanges.pdf
Feel Free to Correct or disagree with any of my information.
Link to Investor relations FAQ's page here:
https://ir.nio.com/resources/investor-faqs
You will find this there:
Maybe NIO announces an uplist attempt....Take the opportunity to calm investors.
...The timing couldn't be more right.
Anyway, according to the other board:
Instead of complete buyouts, I wouldn't doubt larger stakes being purchased and somehow " grandfathered in " ( I refer to any company )
I wouldn't doubt it considering this is new territory ....There's always room for jello
Maybe one scenario is TCEHY buys NIO and Uplists?...and a new game of " hide the pea / shell game " may evolve?
........I dunno ,.apparently an audit would still be needed but as Jeff Goldblum said in Jurassic Park " Life Finds a Way " ...hahaha
....Maybe other companies go that route?... What's your view?
I'm not sure the idea of the U.S. delisting Chinese companies from major domestic exchanges will ever pass, but it's likely to pick up steam.
If it forks into a No NEW listings, then we could see a rally in Chinese companies already listed stateside......
If we go in the direction of NO listings without an audit, then it would be troubling for existing Chinese listings, and a benefit to their foreign alternatives or foreign competitors. (eg. American Companies )
I say this next paragraph in general,not directed to anyone particular ( wink wink ):
I'm open to ALL sides,,,......I Don't Blow Smoke in people's faces and I try to see all sides but I don't need numbers CONSTANTLY pushed in my face..( it really annoys me )....I try being very respectful but I know how certain posters are,,,As an electrician on very large construction sites I'm very good at setting that crap straight.
NIO is a $3 stock therefore, OF COURSE, There are issues......I Don't know a $3 Stock WITHOUT Issues, ......So Please Don't Force it on me.